Market revenue in 2021 | USD 24.2 million |
Market revenue in 2030 | USD 58.4 million |
Growth rate | 10.3% (CAGR from 2021 to 2030) |
Largest segment | Clinical |
Fastest growing segment | Preclinical |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Preclinical, Clinical |
Key market players worldwide | Labcorp Holdings Inc, IQVIA Holdings Inc, Syneos Health, SGS AG, Toxikon, Intertek Group PLC, Pace Analytical Services, Icon PLC, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule bioanalytical testing services market will help companies and investors design strategic landscapes.
Clinical was the largest segment with a revenue share of 66.12% in 2021. Horizon Databook has segmented the India large molecule bioanalytical testing services market based on preclinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
Improvement in number of clinical trials in the country will boost demand for large-scale bioanalytical testing. For instance, India conducted 27,638 clinical trials between 1999 and 2019, according to WHO’s ICTRP. This accounted for 5.27% of total clinical trials conducted globally in the same period.
Furthermore, according to the World Bank, the current healthcare expenditure of India was 3.5% of its GDP in 2018. However, Indian government has more than doubled its healthcare spending for the fiscal year 2020- 2021 in the union budget, with the intention of boosting the healthcare sector.
Such favorable government initiatives are expected to propel market growth. According to India Brand Equity Foundation (IBEF), Indian pharma companies invested 8.8% of their sales revenue on R&D in 2018. The rising pharmaceutical R&D investment in the country will also boost growth.
Horizon Databook provides a detailed overview of country-level data and insights on the India large molecule bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into India large molecule bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account